(S1 (S (S (NP (NN AML1/RUNX1)) (VP (VBZ functions) (PP (IN as) (NP (NP (DT a) (JJ cytoplasmic) (NN attenuator)) (PP (IN of) (NP (NN NF-kappaB) (NN signaling))))) (PP (IN in) (NP (NP (DT the) (NN repression)) (PP (IN of) (NP (JJ myeloid) (NNS tumors))))))) (. .)))
(S1 (S (S (NP (NP (JJ Functional) (NN deregulation)) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (PP (IN in) (NP (NP (JJ many) (NNS types)) (PP (IN of) (NP (NNS tumors))))))))) (. .)))
(S1 (S (S (S (NP (NN Transcription) (NN factor) (NN AML1/RUNX1)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ frequent)) (NNS targets)) (PP (IN of) (NP (NP (JJ chromosomal) (NNS abnormalities)) (PP (IN in) (NP (JJ human) (NN leukemia)))))))))) (CC and) (S (NP (NP (JJ altered) (NN function)) (PP (IN of) (NP (NN AML1)))) (VP (VBZ is) (ADVP (RB closely)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ malignant) (NN transformation)) (PP (IN of) (NP (JJ hematopoietic) (NNS cells))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NP (JJ molecular) (NN basis)) (CC and) (NP (JJ therapeutic) (NNS targets))) (PP (IN of) (NP (JJ AML1-related) (NN leukemia)))) (VP (VBP are) (ADVP (RB still)) (ADJP (JJ elusive)))) (. .)))
(S1 (S (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD explored) (NP (NP (JJ immediate) (NN target) (NNS pathways)) (PP (IN of) (NP (NN AML1)))) (PP (IN by) (NP (NP (ADJP (ADJP (FW in) (FW vitro)) (ADJP (JJ synchronous))) (NN inactivation)) (PP (IN in) (NP (JJ hematopoietic) (NNS cells))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NN AML1)) (VP (VBZ inhibits) (NP (NN NF-kappaB) (NN signaling)) (PP (IN through) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (NN IkappaB) (NN kinase) (NN complex)) (PP (IN in) (NP (DT the) (NN cytoplasm)))))))))))) (. .)))
(S1 (S (ADVP (RB Remarkably)) (, ,) (S (S (NP (NP (NN AML1) (NNS mutants)) (VP (VBN found) (PP (IN in) (NP (JJ myeloid) (NNS tumors))))) (VP (VBP lack) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB inhibit) (NP (NN NF-kappaB) (NN signaling)))))))) (, ,) (CC and) (S (NP (NP (JJ human) (NNS cases)) (PP (IN with) (NP (JJ AML1-related) (NN leukemia)))) (VP (VBZ exhibits) (NP (ADJP (RB distinctly) (VBN activated)) (NN NF-kappaB) (NN signaling))))) (. .)))
(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappaB) (NN signaling))) (PP (IN in) (NP (JJ leukemic) (NNS cells))) (PP (IN with) (NP (VBN mutated) (NN AML1)))) (ADVP (RB efficiently)) (VP (VBZ blocks) (NP (NP (PRP$ their) (NP (NN growth)) (CC and) (NP (NN development))) (PP (IN of) (NP (NN leukemia))))) (. .)))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VP (VBP reveal) (NP (NP (DT a) (JJ novel) (NN role)) (PP (IN for) (NP (NN AML1))) (PP (IN as) (NP (NP (DT a) (JJ cytoplasmic) (NN attenuator)) (PP (IN of) (NP (NN NF-kappaB) (NN signaling))))))) (CC and) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN NF-kappaB) (NN signaling)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ promising) (JJ therapeutic) (NNS targets)) (PP (IN of) (NP (NP (JJ hematologic) (NNS malignancies)) (PP (IN with) (NP (NN AML1) (NN abnormality)))))))))))))) (. .)))
